SULT1C2 is a phase II conjugating enzyme that catalyzes sulfate conjugation of phenolic compounds using 3'-phospho-5'-adenylyl sulfate (PAPS) as a sulfate donor 1. The enzyme exhibits substrate specificity, effectively sulfating phenolic compounds like p-nitrophenol but showing no activity toward steroids, dopamine, acetaminophen, or alpha-naphthol 2. SULT1C2 demonstrates tissue-specific expression patterns, with highest levels in kidney, followed by stomach and liver, and undergoes developmental regulation with elevated expression in prenatal and infant liver compared to adult tissue 3. The enzyme's expression is regulated by multiple nuclear receptors, including vitamin D receptor, liver X receptor, and farnesoid X receptor, with responsive elements located within intron 1 of the gene 4. In cancer contexts, SULT1C2 shows complex roles: it promotes hepatocellular carcinoma progression by enhancing glycolysis and fatty acid metabolism 5, while in lung adenocarcinoma, higher expression correlates with improved survival in smokers and is regulated by cigarette smoke condensate through aryl hydrocarbon receptor activation 6. The enzyme can metabolize carcinogenic compounds like N-hydroxy-2-acetylaminofluorene, potentially contributing to DNA adduct formation and mutagenesis, highlighting its dual role in xenobiotic detoxification and bioactivation pathways.